Stockscreener 앱 받기
736.88
4.88%
34.12
전일 마감가:
$702.75
열려 있는:
$725
하루 거래량:
1.56M
Relative Volume:
1.46
시가총액:
$76.79B
수익:
$14.25B
순이익/손실:
$4.58B
주가수익비율:
17.64
EPS:
41.7701
순현금흐름:
$3.88B
1주 성능:
+6.05%
1개월 성능:
+27.79%
6개월 성능:
+19.89%
1년 성능:
-0.85%
1일 변동 폭
$720.02
$753.51
1주일 범위
$685.95
$753.51
52주 변동 폭
$476.49
$800.99
리제네론 파마슈티컬스 Stock (REGN) Company Profile
명칭
Regeneron Pharmaceuticals Inc
전화
(914) 847-7000
주소
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
REGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
737.17 | 73.86B | 14.25B | 4.58B | 3.88B | 41.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
420.66 | 106.82B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.10 | 60.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
914.47 | 56.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
200.17 | 43.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
리제네론 파마슈티컬스 Stock (REGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-13 | 개시 | Scotiabank | Sector Perform |
| 2025-08-14 | 개시 | Rothschild & Co Redburn | Buy |
| 2025-06-30 | 다운그레이드 | Argus | Buy → Hold |
| 2025-05-30 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-02-05 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-14 | 개시 | Citigroup | Neutral |
| 2024-09-24 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | 개시 | Bernstein | Outperform |
| 2024-01-12 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-03 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | 재확인 | Oppenheimer | Perform |
| 2023-06-28 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-03-23 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2023-01-20 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-10-26 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-09-09 | 업그레이드 | Jefferies | Underperform → Hold |
| 2022-09-09 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-06-06 | 개시 | Jefferies | Underperform |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-01-05 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-01-03 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | 재개 | Wells Fargo | Overweight |
| 2021-12-07 | 재개 | Cowen | Market Perform |
| 2021-12-06 | 개시 | Goldman | Buy |
| 2021-11-19 | 재개 | BMO Capital Markets | Outperform |
| 2021-11-05 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-06-29 | 개시 | H.C. Wainwright | Buy |
| 2021-01-25 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-01-08 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-10-05 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2020-07-09 | 업그레이드 | SunTrust | Hold → Buy |
| 2020-05-26 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-04-17 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2020-04-08 | 개시 | The Benchmark Company | Hold |
| 2020-03-31 | 개시 | Wolfe Research | Peer Perform |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-02-26 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-02-11 | 업그레이드 | Argus | Hold → Buy |
| 2019-12-24 | 개시 | Raymond James | Mkt Perform |
| 2019-12-16 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-12-13 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | 개시 | SunTrust | Hold |
| 2019-11-07 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
모두보기
리제네론 파마슈티컬스 주식(REGN)의 최신 뉴스
Regeneron Wins FDA Nod For Eylea HD With Reduced Injection Schedule For Patients With Vision Loss - Benzinga
Wells Fargo Raises Price Target for REGN to $700 | REGN Stock Ne - GuruFocus
Seizert Capital Partners LLC Has $45.14 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
FDA Hands Regeneron Two Eylea HD Nods in One Day - BioSpace
Regeneron’s Eylea franchise boosted by pair of FDA approvals - Yahoo Finance
United States AMD Drug Market 2025: Get Exclusive Data | Top 5 - openPR.com
Intrust Bank NA Trims Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Raymond James Adjusts PT on Regeneron Pharmaceuticals to $800 From $723, Keeps Outperform Rating - MarketScreener
With new approvals, Regeneron’s higher-dose Eylea gets more competitive - Yahoo Finance
Nomura Asset Management Co. Ltd. Trims Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Why Regeneron Pharmaceuticals Inc. (RGO) stock is favored by hedge fundsProfit Target & Weekly Momentum Stock Picks - newser.com
Rockefeller Capital Management L.P. Trims Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Meridian Wealth Management LLC Lowers Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Stocks to Watch Thursday: Walmart, Nvidia, Exact Sciences, Regeneron - The Wall Street Journal
How strong is Regeneron Pharmaceuticals Inc. stock balance sheetTreasury Yields & Daily Market Momentum Tracking - newser.com
Why analysts raise outlook for Regeneron Pharmaceuticals Inc. (RGO) stockQuarterly Profit Review & Capital Efficiency Focused Strategies - newser.com
How Regeneron Pharmaceuticals Inc. (RGO) stock responds to job market shiftsMarket Volume Report & Advanced Swing Trade Entry Plans - newser.com
Stocks to Watch : Nvidia, Kulicke & Soffa, Regeneron - MarketScreener
Regeneron (REGN) Gains FDA Approval for Eylea HD Injection - GuruFocus
Regeneron Announces Plans To Establish New Drug Manufacturing Facility In Saratoga Springs NY - Pharmaceutical Online
Regeneron Gets FDA Approval for Eylea to Treat Macular Edema - MarketScreener
Regeneron gets FDA nod for Eylea in macular edema treatment - Seeking Alpha
FDA Approves Eylea HD Injection from Regeneron (REGN) for Eye Conditions - GuruFocus
FDA approves EYLEA HD for retinal vein occlusion with extended dosing - Investing.com Canada
Regeneron stock rises as EYLEA HD gets FDA approval for new indication - Investing.com Canada
Regeneron Announces FDA Approval of EYLEA HD® for Retinal Vein Occlusion with New Dosing Options - Quiver Quantitative
Regeneron (NASDAQ: REGN) secures FDA approval for EYLEA HD in RVO with 8-week option and monthly dosing - Stock Titan
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected - simplywall.st
What does recent volatility data suggest for Regeneron Pharmaceuticals Inc.IPO Watch & Risk Managed Investment Signals - newser.com
How currency fluctuations impact Regeneron Pharmaceuticals Inc. stockMarket Volume Summary & Reliable Momentum Entry Alerts - newser.com
Can Regeneron Pharmaceuticals Inc. stock hit record highs again2025 AllTime Highs & Detailed Earnings Play Alerts - newser.com
Regeneron (REGN) Gains EU Approval for Expanded Use of Libtayo - GuruFocus
Can a trend reversal in Regeneron Pharmaceuticals Inc. lead to recoveryWeekly Investment Summary & Low Volatility Stock Recommendations - newser.com
Regeneron gets EU nod for expanded approval of Libtayo (REGN:NASDAQ) - Seeking Alpha
Regeneron Pharmaceuticals Gets European Commission's Approval for Expanded Indication for Libtayo - MarketScreener
European Commission Approves the Pd-1 Inhibitor Libtayo of Regeneron Pharmaceuticals, Inc - MarketScreener
REGN: European Approval for Regeneron's Libtayo in Skin Cancer T - GuruFocus
Regeneron (REGN) EC Approves Libtayo as First Adjuvant CSCC Immunotherapy, 68% Risk Cut - Stock Titan
How Regeneron Pharmaceuticals Inc. stock responds to policy changesMarket Volume Summary & Weekly High Conviction Ideas - newser.com
United States Bispecific T-cell Engagers (BiTEs) Market Size, - openPR.com
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Raiffeisen Bank International AG - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by ARS Investment Partners LLC - MarketBeat
Can Regeneron Pharmaceuticals Inc. stock weather global recessionStop Loss & Growth Focused Investment Plans - newser.com
Why Regeneron Pharmaceuticals Inc. (RGO) stock is listed among top recommendationsJuly 2025 News Drivers & Reliable Breakout Stock Forecasts - newser.com
Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Citigroup Inc. - MarketBeat
Feds Look to 'False Certification' FCA Strategy - Law360
Semanteon Capital Management LP Sells 1,123 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
How Regeneron’s FDA Approvals and Recent Price Jump Impact Its 2025 Valuation - simplywall.st
리제네론 파마슈티컬스 (REGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.49%
0.21%
자본화:
|
볼륨(24시간):